4 research outputs found

    Nanostructured Melt-Spun Sm(Co,Fe,Zr,B)7:5 Alloys for High-Temperature Magnets

    Full text link
    High coercivity, the highest for Cu-free 2 : 17 Sm-Co ribbons, has been obtained in as-spun (= 211 kOe) and short time annealed (= 232 kOe) samples of Sm(CobalFe Zr B)7 5 alloys, with varying B, Zr, and Fe content (= 0-0 06, = 0-0 16, = 0 08-0 3) and wheel speed. In as-spun samples, the TbCu7 type structure and in annealed samples the Th2Zn17 and CaCu5 type structures is observed, plus fcc Co as minority phase is observed. Reduced remanence () is higher than 0.7. High-temperature magnetic measurements show very good stability above 300 C with coercive field as high as 5.2 kOe at 330 C. For annealed Sm(CobalFe0 3Zr0 02B0 04)7 5, very good loop squareness and high maximum energy product of 10.7 MGOe have been obtained. Increasing Zr content results in less uniform microstructure of annealed ribbons.Comment: IEEE Transactions on Magnetics, Vol. 39, No. 5, pages 2869 - 2871, September 200

    The interplay of viral loads, clinical presentation, and serological responses in SARS-CoV-2 – Results from a prospective cohort of outpatient COVID-19 cases

    No full text
    Puchinger K, Castelletti N, Rubio-Acero R, et al. The interplay of viral loads, clinical presentation, and serological responses in SARS-CoV-2 – Results from a prospective cohort of outpatient COVID-19 cases. Virology. 2022;569:37-43

    The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant

    Get PDF
    Le Gleut R, Plank M, Pütz P, et al. The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant. BMC Infectious Diseases. 2023;23(1): 466.**Background** Population-based serological studies allow to estimate prevalence of SARS-CoV-2 infections despite a substantial number of mild or asymptomatic disease courses. This became even more relevant for decision making after vaccination started. The KoCo19 cohort tracks the pandemic progress in the Munich general population for over two years, setting it apart in Europe. **Methods** Recruitment occurred during the initial pandemic wave, including 5313 participants above 13 years from private households in Munich. Four follow-ups were held at crucial times of the pandemic, with response rates of at least 70%. Participants filled questionnaires on socio-demographics and potential risk factors of infection. From Follow-up 2, information on SARS-CoV-2 vaccination was added. SARS-CoV-2 antibody status was measured using the Roche Elecsys® Anti-SARS-CoV-2 anti-N assay (indicating previous infection) and the Roche Elecsys® Anti-SARS-CoV-2 anti-S assay (indicating previous infection and/or vaccination). This allowed us to distinguish between sources of acquired antibodies. **Results** The SARS-CoV-2 estimated cumulative sero-prevalence increased from 1.6% (1.1-2.1%) in May 2020 to 14.5% (12.7-16.2%) in November 2021. Underreporting with respect to official numbers fluctuated with testing policies and capacities, becoming a factor of more than two during the second half of 2021. Simultaneously, the vaccination campaign against the SARS-CoV-2 virus increased the percentage of the Munich population having antibodies, with 86.8% (85.5-87.9%) having developed anti-S and/or anti-N in November 2021. Incidence rates for infections after (BTI) and without previous vaccination (INS) differed (ratio INS/BTI of 2.1, 0.7-3.6). However, the prevalence of infections was higher in the non-vaccinated population than in the vaccinated one. Considering the whole follow-up time, being born outside Germany, working in a high-risk job and living area per inhabitant were identified as risk factors for infection, while other socio-demographic and health-related variables were not. Although we obtained significant within-household clustering of SARS-CoV-2 cases, no further geospatial clustering was found. **Conclusions** Vaccination increased the coverage of the Munich population presenting SARS-CoV-2 antibodies, but breakthrough infections contribute to community spread. As underreporting stays relevant over time, infections can go undetected, so non-pharmaceutical measures are crucial, particularly for highly contagious strains like Omicron

    Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

    Get PDF
    corecore